2022
A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020
Schuster JE, Halasa NB, Nakamura M, Levy ER, Fitzgerald JC, Young CC, Newhams MM, Bourgeois F, Staat MA, Hobbs CV, Dapul H, Feldstein LR, Jackson AM, Mack EH, Walker TC, Maddux AB, Spinella PC, Loftis LL, Kong M, Rowan CM, Bembea MM, McLaughlin GE, Hall MW, Babbitt CJ, Maamari M, Zinter MS, Cvijanovich NZ, Michelson KN, Gertz SJ, Carroll CL, Thomas NJ, Giuliano JS, Singh AR, Hymes SR, Schwarz AJ, McGuire JK, Nofziger RA, Flori HR, Clouser KN, Wellnitz K, Cullimore ML, Hume JR, Patel M, Randolph AG, Investigators O. A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020. Journal Of The Pediatric Infectious Diseases Society 2022, 11: piab123-. PMID: 35022779, PMCID: PMC8807297, DOI: 10.1093/jpids/piab123.Peer-Reviewed Original ResearchConceptsCOVID-19-directed therapiesAcute coronavirus disease 2019Life-threatening COVID-19COVID-19Acute COVID-19Underlying medical conditionsIntensive care unitHigh-acuity careCoronavirus disease 2019Half of childrenYears of ageCharacteristics of childrenRemdesivir useSystemic steroidsRespiratory supportClinical courseCare unitPediatric hospitalSpecific therapyPediatric dataIll childrenLaboratory valuesDisease 2019Medical conditionsUS hospitals
2018
Trauma and Neurodevelopmental Disorders from a Public Health Perspective
Lowe S, Walsh K, Opthof E, Tineo P. Trauma and Neurodevelopmental Disorders from a Public Health Perspective. 2018, 205-239. DOI: 10.1007/978-3-030-00503-0_11.Peer-Reviewed Original ResearchMental health conditionsLow socioeconomic statusPublic health perspectiveTrauma-related disordersTrauma exposureNeurodevelopmental disordersEpidemiologic literatureStress disorderHealth conditionsSocioeconomic statusHealth perspectivePopulation-based studyAcute stress disorderHalf of childrenPublic health interventionsPost-traumatic stress disorderTertiary prevention effortsStressor-related disordersAttention deficit hyperactivity disorderMental health impactPrior trauma exposureTrauma-related conditionsDeficit hyperactivity disorderMore traumatic eventsTrauma-exposed youth
2017
Imipramine for refractory daytime incontinence in the pediatric population
Franco I, Arlen AM, Collett-Gardere T, Zelkovic PF. Imipramine for refractory daytime incontinence in the pediatric population. Journal Of Pediatric Urology 2017, 14: 58.e1-58.e5. PMID: 29100969, DOI: 10.1016/j.jpurol.2017.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesDatabases, FactualDiurnal EnuresisDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansImipramineLower Urinary Tract SymptomsMaleQuality of LifeRetrospective StudiesRisk AssessmentSeverity of Illness IndexTreatment OutcomeUrinary IncontinenceUrodynamicsConceptsVancouver Symptom ScorePercutaneous tibial nerve stimulationTranscutaneous electrical nerve stimulationInternational Children's Continence SocietyLower urinary tractSide effectsAlpha blockersDaytime incontinenceNerve stimulationTreatment responseParasacral transcutaneous electrical nerve stimulationNon-selective alpha blockersPartial response groupTreat response rateSubsequent clinic visitsTibial nerve stimulationElectrical nerve stimulationAdditional treatment modalitiesComplete treatment responseHalf of childrenYears of ageBowel programRefractory incontinenceUrology referralClinic visits
2012
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan D, Tollefsen S, Wilfley D, Kaufman F. A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes. New England Journal Of Medicine 2012, 366: 2247-2256. PMID: 22540912, PMCID: PMC3478667, DOI: 10.1056/nejmoa1109333.Peer-Reviewed Original ResearchConceptsType 2 diabetesDurable glycemic controlGlycated hemoglobin levelsGlycemic controlLifestyle interventionPrimary outcomeHemoglobin levelsRecent-onset type 2 diabetesIntensive lifestyle interventionSerious adverse eventsLifestyle intervention programAddition of rosiglitazoneNon-Hispanic black participantsHalf of childrenYears of ageAdverse eventsPatients 10Prespecified analysisMetabolic decompensationRate of failureTreatment regimensClinical trialsMetforminType 2Rosiglitazone
2009
Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 884-893. PMID: 19625978, PMCID: PMC3943246, DOI: 10.1097/chi.0b013e3181b26e9f.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-AgonistsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildComorbidityContraindicationsDose-Response Relationship, DrugDouble-Blind MethodHumansMethylphenidatePropylaminesPsychotropic DrugsRandomized Controlled Trials as TopicTic DisordersTourette SyndromeConceptsAlpha-2 agonistsAttention-deficit/hyperactivity disorderTic symptomsComorbid ticsSupratherapeutic dosesTic disordersADHD symptomsTreatment of ADHDHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsStandardized mean differenceEvidence-based treatmentsHalf of childrenComorbid tic disordersPrimary outcomeDifferent medicationsPsychostimulant medicationPubMed searchTic severityTourette syndromePackage insertsDrug AdministrationAtomoxetineSymptoms
2000
Neuroimaging in Children With Newly Diagnosed Epilepsy: A Community-Based Study
Berg A, Testa F, Levy S, Shinnar S. Neuroimaging in Children With Newly Diagnosed Epilepsy: A Community-Based Study. 2000, 106: 527-532. PMID: 10969098, DOI: 10.1542/peds.106.3.527.Peer-Reviewed Original ResearchConceptsFocal EEG abnormalitiesPartial seizuresEpilepsy syndromesEEG abnormalitiesLocalization-related epilepsy syndromesEvaluation of seizuresIdiopathic generalized epilepsyCommunity-based studyForms of epilepsyEvaluation of childrenHalf of childrenMagnetic resonance imagingNeurologic deficitsElectroencephalographic findingsInitial diagnosisCerebral malformationsGeneralized epilepsyCavernous angiomaPediatric epilepsyTomography scanArteriovenous malformationsTuberous sclerosisRelevant abnormalitiesInternational LeagueEpilepsy
1994
AIDS‐Related Dementia and Calcium Homeostasisa
LIPTON S. AIDS‐Related Dementia and Calcium Homeostasisa. Annals Of The New York Academy Of Sciences 1994, 747: 205-224. PMID: 7847672, DOI: 10.1111/j.1749-6632.1994.tb44411.x.Peer-Reviewed Original ResearchConceptsNeuronal injuryN-methyl-D-aspartate (NMDA) receptor-operated channelsHuman immunodeficiency virus type 1Arachidonic acidHIV-1 envelope protein gp120Immunodeficiency virus type 1Existence of HIVDeath of neuronsBrains of patientsCalcium channel antagonistsVoltage-dependent Ca2Interleukin-1 betaReceptor-operated channelsFuture pharmacological interventionsFinal common pathwayAmyotrophic lateral sclerosisHalf of childrenEnvelope protein gp120Platelet-activating factorThird of adultsVirus type 1Dysfunction of cognitionGamma interferon stimulationNeuropathic painAIDS dementiaUpdate on current models of HIV-related neuronal injury: Platelet-activating factor, arachidonic acid and nitric oxide
Lipton S, Yeh M, Dreyer E. Update on current models of HIV-related neuronal injury: Platelet-activating factor, arachidonic acid and nitric oxide. Advances In Neuroimmunology 1994, 4: 181-188. PMID: 7874385, DOI: 10.1016/s0960-5428(06)80255-x.Peer-Reviewed Original ResearchConceptsMacrophages/microgliaNeuronal injuryPlatelet-activating factorArachidonic acidHuman immunodeficiency virus type 1Nitric oxideHIV-1 envelope protein gp120Immunodeficiency virus type 1N-methyl-D-aspartate agonistExistence of HIVBrains of patientsHalf of childrenEnvelope protein gp120Third of adultsVirus type 1Dysfunction of cognitionDemise of neuronsNeurological manifestationsImmunodeficiency syndromeAIDS patientsProtein gp120Neurotoxic substancesHIVMonocytoid cellsExcessive influx
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply